Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(12):1849–1853. doi: 10.1038/bjc.1997.315

Prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder.

L Moltó 1, J Carballido 1, L Manzano 1, E Reyes 1, C Olivier 1, M Alvarez-Mon 1
PMCID: PMC2223628  PMID: 9192993

Abstract

The immunomodulatory effect of prophylactic intravesical instillations of interferon alpha 2b (IFN-alpha-2b) on interferon gamma (IFN-gamma) and interleukin 4 (IL-4) production by peripheral blood mononuclear cells (PBMCs) from patients with superficial transitional cell carcinoma (STCC) of the bladder has been analysed. There were no significant differences in the production of IFN-gamma and IL-4 by PBMCs from untreated patients and healthy control subjects after 24 h of phytohaemagglutinin (PHA) stimulation. However, between 3 and 6 months after finishing the prophylactic intracavitary treatment with IFN-alpha-2b, PHA-stimulated PBMCs from patients with STCC of the bladder showed a significantly enhanced production of IFN-gamma and a significantly decreased production of IL-4. Both IFN-gamma and IL-4 returned to pretreatment levels 1 year after ending the treatment. In conclusion, prophylactic intravesical instillations of IFN-alpha-2b in patients with STCC of the bladder have an immunoregulatory effect on the production of IFN-gamma and IL-4 by PBMCs.

Full text

PDF
1849

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Einat M., Resnitzky D., Kimchi A. Close link between reduction of c-myc expression by interferon and, G0/G1 arrest. Nature. 1985 Feb 14;313(6003):597–600. doi: 10.1038/313597a0. [DOI] [PubMed] [Google Scholar]
  2. Glashan R. W. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol. 1990 Sep;144(3):658–661. doi: 10.1016/s0022-5347(17)39547-2. [DOI] [PubMed] [Google Scholar]
  3. Hayakawa K., Salmeron M. A., Kornbluth J., Bucana C., Itoh K. The role of IL-4 in proliferation and differentiation of human natural killer cells. Study of an IL-4-dependent versus an IL-2-dependent natural killer cell clone. J Immunol. 1991 Apr 1;146(7):2453–2460. [PubMed] [Google Scholar]
  4. Heinzel F. P., Sadick M. D., Holaday B. J., Coffman R. L., Locksley R. M. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med. 1989 Jan 1;169(1):59–72. doi: 10.1084/jem.169.1.59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Higuchi C. M., Thompson J. A., Lindgren C. G., Gillis S., Widmer M. B., Kern D. E., Fefer A. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro. Cancer Res. 1989 Dec 1;49(23):6487–6492. [PubMed] [Google Scholar]
  6. Ikemoto S., Kishimoto T., Wada S., Nishio S., Maekawa M. Clinical studies on cell-mediated immunity in patients with urinary bladder carcinoma: blastogenic response, interleukin-2 production and interferon-gamma production of lymphocytes. Br J Urol. 1990 Apr;65(4):333–338. doi: 10.1111/j.1464-410x.1990.tb14751.x. [DOI] [PubMed] [Google Scholar]
  7. Jurincic C. D., Engelmann U., Gasch J., Klippel K. F. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J Urol. 1988 Apr;139(4):723–726. doi: 10.1016/s0022-5347(17)42610-3. [DOI] [PubMed] [Google Scholar]
  8. Kaempfer R., Gerez L., Farbstein H., Madar L., Hirschman O., Nussinovich R., Shapiro A. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol. 1996 Jun;14(6):1778–1786. doi: 10.1200/JCO.1996.14.6.1778. [DOI] [PubMed] [Google Scholar]
  9. Kasahara T., Hooks J. J., Dougherty S. F., Oppenheim J. J. Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. J Immunol. 1983 Apr;130(4):1784–1789. [PubMed] [Google Scholar]
  10. Lamm D. L., Griffith G., Pettit L. L., Nseyo U. O. Current perspectives on diagnosis and treatment of superficial bladder cancer. Urology. 1992 Apr;39(4):301–308. doi: 10.1016/0090-4295(92)90202-8. [DOI] [PubMed] [Google Scholar]
  11. Lynch C. F., Platz C. E., Jones M. P., Gazzaniga J. M. Cancer registry problems in classifying invasive bladder cancer. J Natl Cancer Inst. 1991 Mar 20;83(6):429–433. doi: 10.1093/jnci/83.6.429. [DOI] [PubMed] [Google Scholar]
  12. Molto L., Alvarez-Mon M., Carballido J., Manzano L., Guillen C., Prieto A., Olivier C., Rodriguez-Zapata M. Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. Br J Cancer. 1994 Dec;70(6):1247–1251. doi: 10.1038/bjc.1994.481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Moltó L., Alvarez-Mon M., Carballido J., Olivier C., Gimeno F., Manzano L. Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer. Cancer. 1995 Jun 1;75(11):2720–2726. doi: 10.1002/1097-0142(19950601)75:11<2720::aid-cncr2820751114>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  14. Munakata T., Semba U., Shibuya Y., Kuwano K., Akagi M., Arai S. Induction of interferon-gamma production by human natural killer cells stimulated by hydrogen peroxide. J Immunol. 1985 Apr;134(4):2449–2455. [PubMed] [Google Scholar]
  15. Prescott S., James K., Hargreave T. B., Chisholm G. D., Smyth J. F. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol. 1992 Jun;147(6):1636–1642. doi: 10.1016/s0022-5347(17)37668-1. [DOI] [PubMed] [Google Scholar]
  16. Seder R. A., Paul W. E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol. 1994;12:635–673. doi: 10.1146/annurev.iy.12.040194.003223. [DOI] [PubMed] [Google Scholar]
  17. Singh R. K., Gutman M., Bucana C. D., Sanchez R., Llansa N., Fidler I. J. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4562–4566. doi: 10.1073/pnas.92.10.4562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Spits H., Yssel H., Paliard X., Kastelein R., Figdor C., de Vries J. E. IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures. J Immunol. 1988 Jul 1;141(1):29–36. [PubMed] [Google Scholar]
  19. Torti F. M., Lum B. L. Superficial bladder cancer. Risk of recurrence and potential role for interferon therapy. Cancer. 1987 Feb 1;59(3 Suppl):613–616. doi: 10.1002/1097-0142(19870201)59:3+<613::aid-cncr2820591307>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES